Literature DB >> 25944803

Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array.

Vinod Vathipadiekal1, Victoria Wang2, Wei Wei1, Levi Waldron3, Ronny Drapkin4, Michael Gillette5, Steven Skates6, Michael Birrer7.   

Abstract

PURPOSE: To generate a comprehensive "Secretome" of proteins potentially found in the blood and derive a virtual Affymetrix array. To validate the utility of this database for the discovery of novel serum-based biomarkers using ovarian cancer transcriptomic data. EXPERIMENTAL
DESIGN: The secretome was constructed by aggregating the data from databases of known secreted proteins, transmembrane or membrane proteins, signal peptides, G-protein coupled receptors, or proteins existing in the extracellular region, and the virtual array was generated by mapping them to Affymetrix probeset identifiers. Whole-genome microarray data from ovarian cancer, normal ovarian surface epithelium, and fallopian tube epithelium were used to identify transcripts upregulated in ovarian cancer.
RESULTS: We established the secretome from eight public databases and a virtual array consisting of 16,521 Affymetrix U133 Plus 2.0 probesets. Using ovarian cancer transcriptomic data, we identified candidate blood-based biomarkers for ovarian cancer and performed bioinformatic validation by demonstrating rediscovery of known biomarkers including CA125 and HE4. Two novel top biomarkers (FGF18 and GPR172A) were validated in serum samples from an independent patient cohort.
CONCLUSIONS: We present the secretome, comprising the most comprehensive resource available for protein products that are potentially found in the blood. The associated virtual array can be used to translate gene-expression data into cancer biomarker discovery. A list of blood-based biomarkers for ovarian cancer detection is reported and includes CA125 and HE4. FGF18 and GPR172A were identified and validated by ELISA as being differentially expressed in the serum of ovarian cancer patients compared with controls. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25944803     DOI: 10.1158/1078-0432.CCR-14-3173

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Sparse support vector machines with L0 approximation for ultra-high dimensional omics data.

Authors:  Zhenqiu Liu; David Elashoff; Steven Piantadosi
Journal:  Artif Intell Med       Date:  2019-04-30       Impact factor: 5.326

Review 2.  Epitope prediction and identification- adaptive T cell responses in humans.

Authors:  John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Semin Immunol       Date:  2020-10-31       Impact factor: 11.130

3.  The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer.

Authors:  Zhijie Xu; Bi Peng; Fanhua Kang; Wenqin Zhang; Muzhang Xiao; Jianbo Li; Qianhui Hong; Yuan Cai; Wei Liu; Yuanliang Yan; Jinwu Peng
Journal:  Front Cell Dev Biol       Date:  2022-06-09

4.  Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.

Authors:  Zhanzhan Xu; Yu Zhou; Yexuan Cao; Thi Lan Anh Dinh; Jing Wan; Min Zhao
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

5.  Identifying prognostic signature in ovarian cancer using DirGenerank.

Authors:  Jian-Yong Wang; Ling-Ling Chen; Xiong-Hui Zhou
Journal:  Oncotarget       Date:  2017-07-11

6.  Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Inflammation       Date:  2021-06-06       Impact factor: 4.092

7.  A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

Authors:  Naoto Fujiwara; Masahiro Kobayashi; Austin J Fobar; Ayaka Hoshida; Cesia A Marquez; Bhuvaneswari Koneru; Gayatri Panda; Masataka Taguri; Tongqi Qian; Indu Raman; Quan-Zhen Li; Hiroki Hoshida; Hitomi Sezaki; Hiromitsu Kumada; Ryosuke Tateishi; Takeshi Yokoo; Adam C Yopp; Raymond T Chung; Bryan C Fuchs; Thomas F Baumert; Jorge A Marrero; Neehar D Parikh; Shijia Zhu; Amit G Singal; Yujin Hoshida
Journal:  Med (N Y)       Date:  2021-04-21

8.  Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.

Authors:  Eric Trépo; Nicolas Goossens; Naoto Fujiwara; Won-Min Song; Antonio Colaprico; Astrid Marot; Laurent Spahr; Pieter Demetter; Christine Sempoux; Gene Y Im; Joan Saldarriaga; Thierry Gustot; Jacques Devière; Swan N Thung; Charlotte Minsart; Thomas Sersté; Gianluca Bontempi; Karim Abdelrahman; Jean Henrion; Delphine Degré; Valerio Lucidi; Laura Rubbia-Brandt; Venugopalan D Nair; Christophe Moreno; Pierre Deltenre; Yujin Hoshida; Denis Franchimont
Journal:  Gastroenterology       Date:  2017-11-20       Impact factor: 33.883

9.  Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.

Authors:  Inna Tishchenko; Heloisa Helena Milioli; Carlos Riveros; Pablo Moscato
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

10.  Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Amata Amy Soriano; Antonella Monticelli; Ornella Affinito; Sergio Cocozza; Mariastella Zannini
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.